Cubist Pharmaceuticals Inc. (CBST)
-NasdaqGS | Prev Close: | 56.11 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 52.00 |
|---|
| Beta: | 0.54 |
|---|
| Next Earnings Date: | 17-Jul-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 36.73 - 56.54 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 877,597 |
|---|
| Market Cap: | 3.66B |
|---|
| P/E (ttm): | 31.24 |
|---|
| EPS (ttm): | 1.80 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Cubist Pharmaceuticals Inc. (CBST): Today's Featured Health Care Winnerat TheStreet(Wed, May 22)
- Cubist, Optimer, Trius: Antibiotic Deal Making On Tapat TheStreet(Wed, May 22)
- Cubist Rises On Unusually High Volume (CBST)at TheStreet(Tue, May 21)
- Ahead of the Bell: Analyst upgrades Cubist PharmaAP(Tue, May 21)
- Analysts' Actions: CBST CNW COH TMHC VFCTheStreet(Tue, May 21)
- Cubist price target raised to $63 from $53 at RBC Capitaltheflyonthewall.com(Tue, May 21)
- 2013 FDA Drug Approval Calendarat TheStreet(Tue, May 21)
- Cubist Pharma upgraded by Cantor FitzgeraldBriefing.com(Mon, May 20)
- U.S. court ruling favors Cubist in patent case versus HospiraReuters(Mon, May 20)
- U.S. court ruling favors Cubist in patent case vs Hospiraat Reuters(Mon, May 20)
- Cubist Pharmaceuticals shares leap late after ruling on patent casesat MarketWatch(Mon, May 20)
- Cubist move higher attributed to patent construction in suit against Hospiratheflyonthewall.com(Mon, May 20)
- Cubist Reaches New 52-Week High (CBST)at TheStreet(Mon, May 20)
- Cubist Achieves Top Biotech Ranking in Globe 100 ListBusiness Wire(Sun, May 19)
- A Disconnect Between Future Prospects of Drug Candidates Versus Where Share Price is Currently Trading: Portfolio Manager Finny Kuruvilla Discusses the Biotech and Pharmaceutical SectorsWall Street Transcript(Thu, May 16)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| CBST | 0.00% | 3.66B |
| NVO | 0.00% | 91.83B |
| TEVA | 0.00% | 33.53B |
| AGN | 0.00% | 28.97B |
| FRX | 0.00% | 9.99B |
Key Statistics
| Forward P/E (1 yr): | 31.52 |
|---|
| P/S (ttm): | 3.87 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.23 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.37 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 1.37 |
|---|
Business Summary
Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products for various medical needs in the acute care environment in the United States.
View More